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328A ,IAC(" Fcbru.'~ry 199X 
experimental models, nitric oxide (NO) donors am orgsnic nitrates counteract 
the impoirmont of adenosine (ADO) induced vo~odllototlon rosulllng from NO 
synthesis inhibition, 
Aim of the study was to evaluate the effects of oxogonou~ nitrates on the 
vnsodilator corom'lry rssponso to ADO in 28 patients (21 mNos, ? females; 
21 normoton.stvos, 7hypertensives) with cl~ost pale end nnglographlcally nor- 
mnl corenan/ortnrlos, 14 with negative Nod 14 with posltlvo ECG on effort 
(Control~ end SX, m~pocttvoly), 
Method~: under continuous BP monitoring, diameter of Loll Main (LMD) 
nnd coronnn/flow velocity (CFV) from LAD aden/were meastlrOd by TEE- 
Doppler in basel condition nnd Miter l,v, ADO infuslon (700 t,g/Kg in 5 min) 
mp~ntod twice, before nnd niter t,v. isoaorbldo dinitrnte (I~DN, 2 rag/?, mtn), 
Resl#ts" Control~ and 9X were comparnble for ego, gender, BP, plasma 
glucose ~nd Itpids, LMD wos ~igntlicantly Increased neler ADO (,L3 I 1,0 vs 
4,0 ~ 0,g ram, p - 0,01), snd lurthor alter fSDN (4,5 t 0B ram; p .  0,01 vs, 
basrll and ADO), with no difference between Controls Nod ~X, MCR was not 
significantly affected by ISDN In Controls (ADO: 1,00 t 0,09, ADO *, ISDN 
t,1 4- 0,0g mmHg/cm't~oc t), while In ~X IIl0 MCR wfluo attar ADO .0, ISDN 
was significantly lower Ilion niter ADO alone (ADO 1,23 t 0,1, ADO + ISDN 
0,g6 t 0,1 mmHg/cm'soc ~, p, 0,01), 
Conclos/on~: ADO and ISDN show additive vasodtlotlng oIIocts on opt, 
cotdlsl coronory anenos in Controls and SX; however, ISDN In ~X seems 
to increase the response el coronary mtcrocllCtll.rdlOn to ADC), prebohly by 
mdtqclng an addltlonol coronory ~o~lslanca un~ensltlvn to ADO aloes The,so 
findings ~re in keep,~g with the hypolhosi~ ot on ondoff~el~al dystunchon cotqn, 
teracted by nxegonou,~ NO,donom 
[~KS~ 1I . ,p . l , .d  A. ,Hnons Iod.csd Vaaodllatlan in 
Pstlants With Endoth~l la l  Dys funct ion  
T, ~himadn, Y, IshlbnshL T ~akorlo, ~, InDue, H, Yo~hitomi, Y. Ishinaga, 
K, ~nno, Y, MurNkaml, Shtmnnn M~cal Una,~r~g}, Izumo CgB dn/~ln 
E~,Iokgr~¢tn~; We tested the hypolno~t~ that va',tOrtilNton/effect el ype III I}hOs- 
phodiostetNSe Inhibition with nmrlnono (Amr) might be impaired ~n SubleCts 
wlth endothelial dysfunction 
MothOd,q: Foroalm blood flow (FBF) measurements rttalng tnlraadenal 
inluslOO el ncotylcholmn (Acl~), Amr nnd nltroglyconn (I NL~) were podomod 
using plothysmogrnphy tn t0 pohontS with heart INduro and ago roached 10 
control subloCts wdhout aiflaoiC w%~cul~l d soaso bolero nnd allot ndnc oxide 
syntho,~e blocking with N~'-monBmelhybL-anlinme (LNMMA, .100 ~, reel) 
Fle,~ults: The increment of FBF ~n response to Ach and Amr wore do- 
pressed in patients with I~eafl lnduro eompnirod In conh'ol sobiocts In contrast. 
the effect of TNG on FBF was not different between two gronps L-NMMA stg- 
nllicantly decreased an inc~emont o1 FBF m response to Amr in dose el less 
than 100 ~,glmm, but did no1 alter m dose of 100 ~,g;min and mine (serum 
conoenllatlon 1 fig/tel) 
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Conclusion: Amrinono has vasodilnton/effect, in pod, through nitnc oxide 
synthnso, nnd the effect Is Impaired in subjects with endothelial dysfunction. 
• Effests of L- and D.Arglnlne on the Basal Tone of 
Diseased Coronary Arteries and Their Responses 
to Substsnce P 
C, Tontolouri~, D, Totlsotllls, T, CrNko, G, Kntslmaglls, A Androulakis, 
G.J, Davies, P. TOUtOUZNS, Ct~rdtology Units, Hammersmilh Hospgal London, 
UK; Atlten~ UnivePaify Medlc,.tl School, Greece 
B~lckgroltnd: Administration ot L-mgmme, .'1 substrata in the predict!on o! 
andolhelitlm.derived nltli{; oxide may sfimuloted the release of n!lv!e o~Ide, 
This shldy a~sessnd the effects of substance P admmtstrNIion alone end !n 
combination with L. and Do nrgln!ne in patle~nts with normal ang!ogrNms end 
in patients with antenna/aden/disease, 
Metttod~: Inl[~cotonary inf*,lsions of nemlal maline, the receptor mediated 
nltnc oxidd stlmtdont, substance P (5 6 and 27.8 gruel!ram) before and offer L, 
Or D.~rglnlno (50 and |50 omolhn!nt and uit!~3lycelin 1250 mcg boll.m) were 
administe!ed in 17 patients with coronary adery disease and stable angina, 
and in 6 potlents with norma! anglograms The d~ameter el anglogtaphtcalty 
OOIOI01 pro~inlal and dlslNl segments (SI nnd coronary stonoses were men. 
surod by computerized quantitative an,.liOglaphy 
Ft~sltlts L,al'glnloe administration wits associated with slgnll,~,tnt dddtlon 
hem brlsohno el pTo~lmal S el both "nm'mal" (104 ; 34%,, p . 0 05) and 
diseased (el 5 i 1 5%, P - 00t )  ade.os and ot d~stal (6 7 t I 3%, p.  OO1) S 
el dlseNSOd arlenes No s~gnlhcant changes wore associated with D-algmlno 
ndmlnlshatlon (proximal S OO t 1 1%,, dlsta! S: 0.8 r 0 7%) The n~lgn0udo 
el dilation ot diseased col~.nNl'tes, was groate~ (p. 005) afro! L-argmme and 
substance P infusion (proximal S: 12.7 t 1 8%, distal S: 21.0 :; 2.8%,), than 
alter saline and substance P Infusion (proximal S: 7 1 "~ 1.5°o. distal S: 14 
I 25), or O-nrg~nino nnd substance P infusion (proximal S: 7.4 ; 1 5%. d~stal 
S 147 i 27%) 
Cenclustons D~seased and "normal" coronary artenes dilated in response 
to substance P and In response to L,argmmo but were unaffected by D-mg~- 
rune infusion A sigmhcant proporbon of the response to nltroglyconn coutd be 
obtained by L-argmtno administration. The results are consistent ~,~ith sttmu- 
leben el basal nitric oxide synthase activity in atheromatous coronary adertes 
by L-arg~mno The lack ot potonBabon by L-argmme el the vaseddator re- 
sponse to substance P suggests that this response ~s independent of n~mc 
oxide synthaso substrato avadabildy. 
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Endothehn.t (ET-B ~s a potent vasoconstrictor which ts behoved to play a 
role in the pathogenes~s of a number ot cardiovascular d~seases ~n man 
To investigate the impact on different organ vasculature we prOspectriely 
assessed the effects of a dose range of ET-t infusuons (O0. 0 5, 1 O. 2 0, 
and 2 5 ng/kg~mm) on pulmonary, renal and systemic blood flows measured 
simtdtaneously at basehne, and at one and 3 hours, m a placebo-controlted 
crossovur trial m 8 healthy men. 
Meth~x~s Pulmonary (PBF) and systemic blood t:ows (SBF) were quanta 
toted by Doppler echo as the product of the blood flow velocdy/hme integrals 
and the cross-sectional aruas of the pulmonar~ artery and the left ventncular 
outflow tract obtained from thmr respective diameters LV and RV size and 
hJnction weze assessed by 2D echo and by systohc hme intervals as the rat~o 
of pre-eiechon period (PEP)/Elechon ttme (El T) Etlective renal plasma flow 
(ERPF) was estimaled as the cleauance of pare-amino hnppunc actd. 
~esults: ET-1 caus~.d a dose-dependent redoctzen in mean ERPF. ET-I 
infusion el Z.5 ng/kg, mi:'~ r£:ducdd mean ERPF  by 27 c ~ from 0.59 ~ 003 L/ram 
at baseline to 0.48 ~ 0.03 L/rain (p. 0.05) compared to a 0.1"o change wdh 
placebo. Systohe blood pressure increased by a mean of 9 mm H9 but head 
rate did not change at ET-1 infusion of 2.5 ng/kg/mm. By contrast. ET-1 at 
doses up to 2.5 ng!kg/min did not result in any signiltcant change in LV size, 
stroke volume (65 .~ 11 vs 62 ~ 11 ml), % LV shortening (51 *, 6 vs 49 .. 5), 
PEP/LVEiT (0.40 ~ 0.02 vs 0.41 ~, 0.10), PBF (461 * 0.82 vs 4 98 i 1.13 
L/rain) el in HV PEP/RVEIT (0.36 ~ 0.03 vs 0.36 ~. 0.06) compared to placebo. 
Conclusion: Low doses of exogenous ET-1 has very dtffemnt effects on 
the pulmonary, systemic and renal vascular beds. The renal vasculature is 
e~qubsdely sensitive to the vasoconstrictor action of ET-1, but ET-1 has little 
effect on LV or RV size and function or on modulating systemic or pulmonary 
bided flows in healthy men. 
